Arbutus Biopharma Corporation
ABUS
$4.46
-$0.44-8.98%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 522.19% | 15.14% | -26.62% | -71.25% | -62.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 522.19% | 15.14% | -26.62% | -71.25% | -62.89% |
| Cost of Revenue | -66.58% | -41.84% | -49.84% | -29.23% | -93.68% |
| Gross Profit | 1,607.58% | 48.13% | 53.07% | 16.61% | 104.65% |
| SG&A Expenses | -55.90% | 9.79% | 65.30% | -22.34% | 26.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -61.79% | -28.60% | -23.93% | -27.68% | -2.42% |
| Operating Income | 108.95% | 32.09% | 23.65% | 18.18% | -12.36% |
| Income Before Tax | 112.74% | -37.21% | 35.11% | 1.92% | -15.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 112.74% | -37.21% | 35.11% | 1.92% | -15.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 112.74% | -37.21% | 35.11% | 1.92% | -15.81% |
| EBIT | 108.95% | 32.09% | 23.65% | 18.18% | -12.36% |
| EBITDA | 109.15% | 32.56% | 23.94% | 18.34% | -12.51% |
| EPS Basic | 112.54% | -26.33% | 42.32% | 13.08% | -2.33% |
| Normalized Basic EPS | 114.75% | 38.41% | 33.62% | 29.78% | 2.40% |
| EPS Diluted | 109.09% | -26.33% | 40.05% | 13.08% | -6.90% |
| Normalized Diluted EPS | 114.75% | 38.41% | 33.62% | 29.78% | 2.40% |
| Average Basic Shares Outstanding | 1.87% | 8.59% | 12.52% | 12.83% | 13.23% |
| Average Diluted Shares Outstanding | 2.32% | 8.59% | 12.52% | 12.83% | 13.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |